Drug intelligence / Profile preview

EM-036

Development stage: Unknown
Lead developer: Eumentis Therapeutics
Modality: Small Molecules

Overview

**EM-036** is a bifunctional nitro-aminoadamantane derivative and analogue of memantine, developed as a **N-methyl-D-aspartate receptor (NMDAR) antagonist** with potential neuroprotective properties. It combines nitro and aminoadamantane moieties to enhance its pharmacological profile beyond standard memantine, targeting excessive glutamatergic signaling implicated in neurodegenerative disorders. Initially pursued by Eumentis Therapeutics, development has been discontinued.[1][13]

Other names: nitro-aminoadamantane

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on EM-036.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EM-036.

Explore the full profile